Immunorizon
T-and NK-cell Engagers for Cancer Therapy
Company Overview
Snapshot
Founded in December 2017, Immunorizon operates with 1–10 employees. The company has secured funding across 3 rounds from 2 investors. A significant milestone for Immunorizon was its acquisition by Purple Biotech in February 2023.
Business overview
Immunorizon is a Health Tech & Life Sciences company focused on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company's core technology involves extending its pipeline and utilizing tri-specific constructs with additional tumor-associated antigens and diverse engagers targeting both T-cells and NK-cells. Operating within the Pharmaceuticals sector, Immunorizon addresses the oncology and immunology markets with its biotechnology-driven solutions.
Strategic signal
Immunorizon's acquisition by Purple Biotech in February 2023 signals a strategic consolidation within the biotechnology sector, particularly in cancer therapy. This event suggests a validation of Immunorizon's T- and NK-cell engager technology and indicates a potential acceleration of its pipeline development under new ownership, offering investors insight into the evolving landscape of oncology therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is Immunorizon's primary focus?
- Immunorizon specializes in developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with additional tumor-associated antigens.
- When was Immunorizon acquired?
- Immunorizon was acquired by Purple Biotech in February 2023.
- When did Immunorizon receive its first disclosed funding?
- In December 2017, Immunorizon received seed funding from M Ventures and ExploreBio.
- What is Immunorizon's current product stage?
- Immunorizon's product is currently in the Clinical Trial stage, focusing on developing T- and NK-cell engagers for cancer therapy.